Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046043 | 0.71 | KMT2A (0.51) | MAPTNPC1 | |
| SCHEMBL811754 | 0.71 | GRM5 (0.47) | TGFBR1MAPK14MAPTGRM5NPC1 | |
| SCHEMBL9977744 | 0.70 | CYP4F2 (0.61) | CYP4F2CYP4A11 | |
| SCHEMBL1895492 | 0.70 | KDM4E (0.48) | MAPTNPC1 | |
| Hydrochloric Acid SCHEMBL15327060 | 0.69 | CYP4F2 (0.60) | CYP4F2CYP4A11 | |
| SCHEMBL23416941 | 0.68 | KDR (0.43) | CYP4F2CYP4A11TGFBR1MAPK14MAPT | |
| SCHEMBL4051821 | 0.68 | TGFBR1 (0.34) | CYP4F2CYP4A11TGFBR1MAPK14MAPT | |
| SCHEMBL4051540 | 0.68 | ALPL (0.37) | — | |
| SCHEMBL3835184 | 0.66 | NPC1 (0.44) | MAPK14GRM5NPC1RXFP1 | |
| SCHEMBL4045819 | 0.66 | NOTUM (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589096-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1566384-B1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-20080188507-A1 | Novel azole derivatives | MSD K.K. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7365079-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20060111380-A1 | Novel azole derivatives | MSD K.K. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1566384-A1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188507-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | CYP4F2 305/4885CYP4A11 336/4885TGFBR1 1025/4885 |
| US-20060111380-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | CYP4F2 344/4885CYP4A11 338/4885TGFBR1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.